BMS493 is an inverse pan-retinoic acid receptor (RAR) agonist. BMS493 also could prevent retinoic acid-induced differentiation. BMS493 increases nuclear corepressor interaction with RARs[1][2].

BMS493 (100 nM; 6 days; ALDHhi UCB cells) treatment shows a twofold increase in the number of ALDHhi cells available for transplantation compared with untreated controls. Newly expanded ALDHhi cells shows increased numbers of CD34 and CD133-positive cells. As well as a reduction in CD38 expression, a marker of hematopoietic cell differentiation[1].

Intrapancreatic transplantation of cell progeny after expansion of ALDHhi cells with or without BMS493 shows no reduction of hyperglycemia in Streptozotocin-treated NOD/SCID mice. So Umbilical cord blood (UCB)-derived ALDHhi cells effectively lost islet regenerative capacity during ex vivo expansion[1].

215030-90-3

C29H24O2

404.5

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years